These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 17785576)
1. Targeting lymphotoxin beta receptor with tumor-specific T lymphocytes for tumor regression. Yang D; Ud Din N; Browning DD; Abrams SI; Liu K Clin Cancer Res; 2007 Sep; 13(17):5202-10. PubMed ID: 17785576 [TBL] [Abstract][Full Text] [Related]
2. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109 [TBL] [Abstract][Full Text] [Related]
3. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. Caldwell SA; Ryan MH; McDuffie E; Abrams SI J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387 [TBL] [Abstract][Full Text] [Related]
4. Lymphotoxin-β receptor activation by lymphotoxin-α(1)β(2) and LIGHT promotes tumor growth in an NFκB-dependent manner. Daller B; Müsch W; Röhrl J; Tumanov AV; Nedospasov SA; Männel DN; Schneider-Brachert W; Hehlgans T Int J Cancer; 2011 Mar; 128(6):1363-70. PubMed ID: 20473944 [TBL] [Abstract][Full Text] [Related]
5. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL. Lee SH; Bar-Haim E; Machlenkin A; Goldberger O; Volovitz I; Vadai E; Tzehoval E; Eisenbach L Cancer Gene Ther; 2004 Mar; 11(3):237-48. PubMed ID: 14739939 [TBL] [Abstract][Full Text] [Related]
6. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. Ando K; Hiroishi K; Kaneko T; Moriyama T; Muto Y; Kayagaki N; Yagita H; Okumura K; Imawari M J Immunol; 1997 Jun; 158(11):5283-91. PubMed ID: 9164947 [TBL] [Abstract][Full Text] [Related]
7. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. Kataoka T; Shinohara N; Takayama H; Takaku K; Kondo S; Yonehara S; Nagai K J Immunol; 1996 May; 156(10):3678-86. PubMed ID: 8621902 [TBL] [Abstract][Full Text] [Related]
8. Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand. Liu AN; Mohammed AZ; Rice WR; Fiedeldey DT; Liebermann JS; Whitsett JA; Braciale TJ; Enelow RI Am J Respir Cell Mol Biol; 1999 May; 20(5):849-58. PubMed ID: 10226053 [TBL] [Abstract][Full Text] [Related]
9. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). Winter H; Hu HM; Urba WJ; Fox BA J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388 [TBL] [Abstract][Full Text] [Related]
10. Perforin and Fas induced by IFNgamma and TNFalpha mediate beta cell death by OT-I CTL. McKenzie MD; Dudek NL; Mariana L; Chong MM; Trapani JA; Kay TW; Thomas HE Int Immunol; 2006 Jun; 18(6):837-46. PubMed ID: 16574667 [TBL] [Abstract][Full Text] [Related]
11. Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression. Liu K; Caldwell SA; Abrams SI Cancer Res; 2005 May; 65(10):4376-88. PubMed ID: 15899830 [TBL] [Abstract][Full Text] [Related]
12. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus. Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA J Immunol; 1999 Oct; 163(8):4335-41. PubMed ID: 10510373 [TBL] [Abstract][Full Text] [Related]
13. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen. Saha A; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M Immunology; 2006 Aug; 118(4):483-96. PubMed ID: 16895556 [TBL] [Abstract][Full Text] [Related]
14. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Lowin B; Hahne M; Mattmann C; Tschopp J Nature; 1994 Aug; 370(6491):650-2. PubMed ID: 7520535 [TBL] [Abstract][Full Text] [Related]
15. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism. Williams NS; Engelhard VH J Immunol; 1996 Jan; 156(1):153-9. PubMed ID: 8598456 [TBL] [Abstract][Full Text] [Related]
16. Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements. Tsujimura K; Takahashi T; Iwase S; Matsudaira Y; Kaneko Y; Yagita H; Obata Y J Immunol; 1998 Jun; 160(11):5253-61. PubMed ID: 9605121 [TBL] [Abstract][Full Text] [Related]
17. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production. Kessler B; Hudrisier D; Schroeter M; Tschopp J; Cerottini JC; Luescher IF J Immunol; 1998 Dec; 161(12):6939-46. PubMed ID: 9862728 [TBL] [Abstract][Full Text] [Related]
18. Essential roles of perforin in antigen-specific cytotoxicity mediated by human CD4+ T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells. Yanai F; Ishii E; Kojima K; Hasegawa A; Azuma T; Hirose S; Suga N; Mitsudome A; Zaitsu M; Ishida Y; Shirakata Y; Sayama K; Hashimoto K; Yasukawa M J Immunol; 2003 Feb; 170(4):2205-13. PubMed ID: 12574394 [TBL] [Abstract][Full Text] [Related]
19. Fas-independent cytotoxicity mediated by human CD4+ CTL directed against herpes simplex virus-infected cells. Yasukawa M; Ohminami H; Yakushijin Y; Arai J; Hasegawa A; Ishida Y; Fujita S J Immunol; 1999 May; 162(10):6100-6. PubMed ID: 10229852 [TBL] [Abstract][Full Text] [Related]
20. In vivo analysis of adenovirus-specific cytotoxic T lymphocyte response in mice deficient in CD28, fas ligand, and perforin. Chen J; Hsu HC; Zajac AJ; Wu Q; Yang P; Xu X; McPherson SA; Li J; Curiel DT; Mountz JD Hum Gene Ther; 2006 Jun; 17(6):669-82. PubMed ID: 16776575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]